



## Neurological Diseases: From Molecular Mechanisms to Clinical Practice

Guest Editors:

**Dr. Svetlana Viktorovna  
Demyanenko**

Academy of Biology and  
Biotechnology, Southern Federal  
University, 344090 Rostov-on-  
Don, Russia

**Dr. Denis Silachev**

1. Laboratory of the Structure  
and Function of Mitochondria,  
A.N. Belozersky Institute of  
Physico-Chemical Biology,  
Lomonosov Moscow State  
University, 119992 Moscow,  
Russia  
2. Lab Stem Cells Technology, V.I.  
Kulakov National Medical  
Research Center of Obstetrics,  
Gynecology and Perinatology,  
117997 Moscow, Russia

Deadline for manuscript  
submissions:  
**closed (25 August 2023)**

### Message from the Guest Editors

Dear Colleagues,

The increasing incidence of neurological diseases in young people together with the population's aging, as well as discovery of new mutations that cause neurological disorders are not good indicators for the future. Unfortunately, effective methods of neuroprotection are lacking. The available therapies reduce the neurodegeneration rate to a certain extent but cannot cure or significantly slow down a disease. Many suggested agents were found to protect nerve cells in vitro and in animal brain but were ineffective or caused unacceptable side effects in humans. To find effective neuroprotectors, a profound study of the molecular mechanisms of neurodegeneration and neuroprotection is needed. Between the initial processes leading to damage propagation and the final processes resulting in neurodegeneration or neuroprotection with brain tissue recovery lies a vast field of biochemical signaling connected with transcription and epigenetic mechanisms. This Special Issue will collect reviews and original articles on new approaches to find promising strategies for treating neuropathologies.

Dr. Svetlana Viktorovna Demyanenko

Dr. Denis Silachev

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)